TENET HEALTHCARE CORP executive Paola M. Arbour, EVP and Chief Information Officer, reported acquiring 18,894 shares of common stock through a grant or award on February 13, 2026. The shares were issued at a stated price of $0.0000 per share, bringing her directly held total to 39,004 shares.
According to the disclosure, this grant represents performance-based restricted stock that was earned when the company’s Human Resources Committee certified that applicable performance targets were achieved for the performance period from January 1, 2023 to December 31, 2025.
Tenet Healthcare CEO Saumya Sutaria reported an equity award under the company’s incentive plan. He acquired 245,592 shares of common stock at no cost through a grant of performance-based restricted stock that was earned when the Human Resources Committee certified achievement of performance goals for the period from January 1, 2023 to December 31, 2025. Following this award, his directly held common stock position increased to 620,681 shares.
Tenet Healthcare’s principal accounting officer, Ramsey R. Scott, received an equity award. On the reported date, he acquired 9,448 shares of Tenet Healthcare common stock as a grant of performance-based restricted stock at a price of $0 per share.
Following this grant, his directly held common stock totaled 9,448 shares. The award was earned when the company’s Human Resources Committee certified that performance targets were achieved for the performance period from January 1, 2023 to December 31, 2025, based on the extent to which the applicable performance goals were attained.
Tenet Healthcare Corp executive Thomas W. Arnst reported an equity award of 37,785 shares of common stock. The Form 4 shows these shares were acquired at a price of $0.00 per share as a grant or award, bringing his directly held common stock to 37,785 shares.
According to the footnote, this represents performance-based restricted stock that was earned when the Human Resources Committee certified achievement of performance targets tied to goals measured over the period from January 1, 2023 to December 31, 2025.
Tenet Healthcare Corporation files its annual report describing a large, diversified U.S. healthcare network centered on 50 acute and specialty hospitals and 533 ambulatory surgery centers, plus revenue‑cycle and value‑based care services through Conifer. The company highlights continued investments in higher‑acuity hospital services, new facilities like the 54‑bed Florida Coast Medical Center, and growth in outpatient surgery via USPI joint ventures.
Tenet reports nearly 99,000 employees, significant nurse and physician recruitment challenges, and rising labor costs, including minimum‑wage increases and union activity at 27 hospitals. Management details heavy reliance on managed care, Medicare and Medicaid, noting that policy shifts such as Affordable Care Act subsidy expirations and the new One Big Beautiful Bill Act could reduce coverage, lower supplemental payments and delay government reimbursements. Extensive discussion covers regulatory, antitrust, privacy and cybersecurity obligations, and a formal compliance program aimed at managing fraud‑and‑abuse, HIPAA, and consumer‑protection risks.
Tenet Healthcare reported strong fourth quarter and full-year 2025 results and issued a detailed 2026 outlook. Q4 2025 net income available to common shareholders was $371 million, or $4.22 per diluted share, with adjusted diluted EPS up 36.6% to $4.70. Q4 Adjusted EBITDA rose 12.9% to $1.183 billion, for a 21.4% margin.
For 2025, net operating revenues were $21.31 billion, Adjusted EBITDA was $4.566 billion, and free cash flow reached $2.53 billion, up from $1.116 billion in 2024. The Ambulatory segment delivered 2025 Adjusted EBITDA of $2.026 billion, while the Hospital segment generated $2.54 billion, both with margin expansion.
Tenet highlighted a major Conifer transaction with CommonSpirit, including $1.9 billion of payments to Tenet over three years and approximately $1.65 billion of 2026 revenue from contract termination, alongside about $500 million of tax expense and roughly $150 million of related tax payments. In 2025 the company repurchased 8.8 million shares for $1.386 billion, refinanced debt, and reduced its net debt-to-Adjusted EBITDA ratio to 2.25x from 2.54x.
Tenet Healthcare Corporation expects its Adjusted EBITDA for the year ended December 31, 2025 to be at the upper end of its current guidance range of $4.47 billion to $4.57 billion, signaling stronger-than-planned operating performance.
The company also entered into an Omnibus Agreement with its Conifer subsidiaries and CommonSpirit Health (formerly Catholic Health Initiatives). CHI will pay an aggregate $1.9 billion to Tenet in annual installments over three years, with $540 million satisfied on January 27, 2026 by offsetting an equal amount owed by Conifer Health. Conifer Health is redeeming CHI’s 23.8% equity interest for $540 million, effective January 1, 2026, and the transaction is expected to reduce Tenet’s redeemable non‑controlling interest and other liabilities by about $885 million and increase additional paid‑in capital by about $305 million.
Tenet Healthcare Corp reported an insider equity transaction by CEO and director Saumya Sutaria. On December 31, 2025, 13,016 restricted stock units converted into common stock on a one-for-one basis, increasing his directly held stake.
On the same date, 6,610 shares of common stock were withheld to cover taxes at a price of $198.72 per share. After these transactions, Sutaria directly owned 375,089 shares of Tenet common stock and held 39,049 time-based restricted stock units that continue to vest annually through 2028 under a January 23, 2025 grant.
Tenet Healthcare Corp director Nadja West reported selling 2,178 shares of the company’s common stock on 12/15/2025. The shares were sold at a weighted average price of $197.47 per share in multiple transactions, with prices ranging from $197.47 to $197.57. Following this sale, West beneficially owned 28,480 shares of Tenet Healthcare common stock directly.
THC reports that a holder of its common stock plans to sell 2,178 shares under Rule 144. The sale is expected to be executed through Fidelity Brokerage Services on the NYSE around 12/15/2025, with an aggregate market value of 430,097.46 based on the figures provided.
The shares were acquired on 05/07/2024 through restricted stock vesting from the issuer as compensation. The same table lists 87,885,000 common shares outstanding. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer and, if using a Rule 10b5-1 trading plan, that this representation applied when the plan or trading instructions were adopted.